Výsledky vyhledávání

Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy

Autor: Kazuo Tamura, Olga Ab, Kenji Ishitsuka, Victor S. Goldmacher, Shiro Jimi

Publikováno v: British journal of haematology. 141(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cdda2ce2ac43496d9ae8c2604eb1ed7
https://pubmed.ncbi.nlm.nih.gov/18279455

Zobrazit plný text záznamu

649 POSTER Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

Autor: F.V. Fosella, HS Xie, Ken Donaldson, Penella J. Woll, S. Zildjian, Paul Lorigan, S. Welch, M. O'Brien, R.J. Fram, Y. Clinch

Publikováno v: European Journal of Cancer Supplements. 4:195-196

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03b82c0cc8664aa1973a5b156736cef7
https://doi.org/10.1016/s1359-6349(06)70654-1

Zobrazit plný text záznamu

Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma

Autor: Frank V. Fossella, P. Fidias, J. McCann, R. Raju, Anthony W. Tolcher, Miguel A. Villalona-Calero, R. J. Fram, R. Guild, S. Zildjian

Publikováno v: Journal of Clinical Oncology. 25:18084-18084

18084 Background: HuN901-DM1, a humanized antibody-maytansinoid immunoconjugagte, binds to CD56 which is expressed in almost all cases of SCLC as well as in other small cell carcinomas (SCC), neuroendocrine carcinomas, and multiple myeloma. The immun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d76b01833776be0e45e8c9b5b7c7a0e
https://doi.org/10.1200/jco.2007.25.18_suppl.18084

Zobrazit plný text záznamu

Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

Autor: C. Carr, H. Xie, Anthony W. Tolcher, K. Berg, L.-L. Hwang, J. McCann, Frank V. Fossella, R. Fram

Publikováno v: Journal of Clinical Oncology. 23:7159-7159

7159 Background: BB-10901 is an immunoconjugate created by conjugation of the cytotoxic maytansinoid drug DM1 to a humanized version of the murine monoclonal antibody N901. BB-10901 binds with high...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9989d0ae56d518d470c5a619cab0cd9
https://doi.org/10.1200/jco.2005.23.16_suppl.7159

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání